ARTICLE | Company News
Medicines Co. projects lower Angiomax revenues
April 10, 2015 11:40 PM UTC
The Medicines Co. (NASDAQ:MDCO) said it expects a sharp decline in 1Q15 revenues due to flagging sales of anticoagulant Angiomax bivalirudin.
The company expects total worldwide revenues of $125-$130 million in 1Q15, down 27-29% from $177.2 million in 1Q14 and 29-32% below analyst estimates of $184.2 million. The company expects worldwide bivalirudin revenues in the range of $97-$105 million, down 33-38% from $155.7 million in 1Q14. ...